Benfogamma 150 mg 30 pcs

Benfothiamine is a fat-soluble derivative of thiamine. Thiamine is converted into active thiamine pyrophosphate and as a coenzyme, is included in pyruvate decarboxylase, alpha-ketoglutarate decarboxylase complexes, which participate in the oxidative decarboxylation of pyruvic and alpha-ketoglutaric acid; transketolase – pentose phosphate shunt enzyme.

Pharmacokinetics

Absorption is high, throughout the small intestine. Before absorption it is released from bound state by digestive enzymes. After 15 min it is detected in blood and after 30 min – in other tissues. Blood concentrations are relatively low, with free thiamine circulating mainly in plasma, its phosphorus esters in erythrocytes and leukocytes. Phosphorylation occurs in the liver.

The most active phosphorus ester is thiamindiphosphate, which has coenzyme activity. It accumulates mainly in the liver, heart, brain, kidneys, and spleen. 1/2 of the total amount is found in the transverse striated muscle and myocardium and about 40% in the internal organs. It is excreted through the intestine and the kidneys.

Indications

Polyneuropathy, Alcoholism, Malnutrition

B₁ deficiency confirmed by clinical and biochemical studies, developing against:

• insufficient and inadequate nutrition (beri-beri);
• parenteral nutrition for long periods, hemodialysis;
chronic alcoholism (alcoholic cardiomyopathy, Wernicke’s encephalopathy,
• increased vitamin B₁ need.

Polyneuropathy due to vitamin B₁ deficiency. Typical signs of such deficiency are neurological disorders in the form of neuropathies with sensory disturbances (pain, tingling sensation, loss of sensation in the upper and lower extremities).

Active ingredient

Benfothiamine

Composition

1 dragee contains:

active ingredient:

benfothiamine 150 mg,

excipients:

microcrystalline cellulose 122.0 mg,

povidone K-30 8.0 mg,

fatty acid glycerides 5.0 mg,

colloidal silica 7.0 mg,

sodium carmellose 3.0 mg,

talc 10.0 mg;

coating composition:

shellac 3.0 mg,

sucrose 70.875 mg,

calcium carbonate 66.479 mg,

talc 41.314 mg,

acacia gum 10.155 mg,

corn starch 7.340 mg,

titanium dioxide 10.932 mg,

colloidal silicon dioxide 4.404 mg,

povidone K-30 6.210 mg,

macrogoal-6000 1.597 mg,

Glycerol 85% 2.262 mg,

Polysorbate 80 0.133 mg,

Mountain glycolic wax 0.300 mg

How to take, the dosage

For the treatment of vitamin B₁ deficiency: 1 tablet once a day.

For treatment of polyneuropathies caused by vitamin B₁ deficiency: initial dose of 1 tablet 2 times daily for 3 weeks, then 1 tablet daily.

The duration of treatment depends on its effectiveness and is determined by the doctor.

The tablet is taken without chewing, with a small amount of water.

Interaction

Thiamine weakens the effect of depolarizing myorelaxants (suxamethonium iodide, etc.), is inhibited by fluorouracil.
Ethanol slows the rate of absorption of thiamine after oral administration.

Special Instructions

No adverse reactions other than the above have been noted in the elderly.
It is not recommended to take a double dose of the drug if the previous dose was missed.
In Wernicke’s encephalopathy, administration of dextrose should be preceded by administration of thiamine.

Influence on driving and operating ability
There are no data on the effect of the drug on driving and operating ability used in therapeutic doses.

Contraindications

• Excessive individual sensitivity to the ingredients of the drug,
• sugarose/isomaltose deficiency,

.

• fructose intolerance glucose-galactose malabsorption,
• 1 period of pregnancy,
• childhood.

.

Side effects

Allergic reactions: angioedema, urticaria, itching.

Overdose

Benfogamma 150 has not been observed to overdose to date.

Pregnancy use

Pregnancy is a contraindication for the use of the drug.